German biotech firm BioNTechreportedly plans to establish a regional center and a new production facility for vaccines based on mRNA (messenger RNA) technology in Singapore.
In the statement made by BioNTech, it was stated that the Singapore office, which will be the regional center for Southeast Asia, is planned to open in 2021.
80 PEOPLE EMPLOYMENT WILL BE PROVIDED
In the statement that the company is working to expand its production network, it was stated that the production facility in Singapore is expected to be operational by 2023 and will provide employment for approximately 80 people.
In the statement of BioNTech, it was emphasized that the start of production of the German company in Southeast Asia was supported by the Singapore Economic Development Board (EDB), and it was stated that this would provide a rapid response to future epidemic threats.
BioNTech Senior Manager (CEO) and Founding Partner Prof. Dr. Uğur Şahin stated that Singapore offers an excellent business environment and said, “Having more than one point in our production network is an important strategic step in increasing our global footprint and developing our capabilities.”
Download the NTV application, be informed about the developments
385 THOUSAND PEOPLE EXAMINED: BİONTECH VACCINE IS EFFECTIVE IN EVERY VARIANT